{"id":"5-fluoro-2-deoxycytidine","safety":{"commonSideEffects":[{"rate":"30%","effect":"Neutropenia"},{"rate":"20%","effect":"Thrombocytopenia"},{"rate":"40%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"5-fluoro-2-deoxycytidine is a thymidylate synthase inhibitor that works by interfering with DNA synthesis, leading to cell death in rapidly dividing cancer cells.","oneSentence":"Inhibits thymidylate synthase","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T06:54:18.837Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Colorectal cancer"}]},"trialDetails":[{"nctId":"NCT04929028","phase":"PHASE2","title":"Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-08-09","conditions":"AIDS-Related Anal Carcinoma, Anal Margin Squamous Cell Carcinoma, Anal Non-Keratinizing Squamous Cell Carcinoma","enrollment":40},{"nctId":"NCT04166318","phase":"PHASE2","title":"Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-01-02","conditions":"Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Canal Squamous Cell Carcinoma","enrollment":252},{"nctId":"NCT01534598","phase":"PHASE1","title":"FdCyd and THU for Advanced Solid Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2012-03-05","conditions":"Neoplasms","enrollment":59},{"nctId":"NCT03432741","phase":"PHASE1","title":"Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2018-03-27","conditions":"Breast Adenocarcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma","enrollment":17},{"nctId":"NCT06110598","phase":"PHASE2","title":"CAPEcitabine eXtension of Adjuvant Therapy for Pancreatic Adenocarcinoma: (CAPE-X)","status":"WITHDRAWN","sponsor":"Case Comprehensive Cancer Center","startDate":"2024-12-01","conditions":"Pancreas Cancer, Pancreas Adenocarcinoma","enrollment":""},{"nctId":"NCT01479348","phase":"EARLY_PHASE1","title":"Imaging Study for FdCyd and THU Cancer Treatment","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-11-01","conditions":"Head and Neck Neoplasms, Lung Neoplasms, Urinary Bladder Neoplasms","enrollment":5},{"nctId":"NCT00978250","phase":"PHASE2","title":"A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU)","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-08-20","conditions":"Head and Neck Neoplasms, Lung Neoplasms, Urinary Bladder Neoplasms","enrollment":95},{"nctId":"NCT01632306","phase":"PHASE1, PHASE2","title":"A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2013-03","conditions":"Pancreatic Cancer","enrollment":13},{"nctId":"NCT01989000","phase":"NA","title":"The Role of the Tumor Microenvironment of Pancreatic Cancer to Predict Treatment Outcome","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2013-11","conditions":"Pancreatic Cancer","enrollment":47},{"nctId":"NCT01041443","phase":"PHASE1","title":"5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2009-12","conditions":"Adult Acute Myeloid Leukemia, de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes","enrollment":25},{"nctId":"NCT00359606","phase":"PHASE1","title":"5-Fluoro-2'-Deoxcyctidine and Tetrahydrouridine to Treat Patients With Advanced Cancer","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"1999-04","conditions":"Neoplasms","enrollment":58},{"nctId":"NCT00795678","phase":"","title":"Chemotherapeutic Agents in Brain/Breast","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2008-09","conditions":"Breast Cancer, Metastatic Cancer","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["FdCyd"],"phase":"phase_1","status":"active","brandName":"5-fluoro-2-deoxycytidine","genericName":"5-fluoro-2-deoxycytidine","companyName":"City of Hope Medical Center","companyId":"city-of-hope-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Inhibits thymidylate synthase Used for Colorectal cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}